Overview
Hemizygous deletion of the beta-globin gene cluster leading to Hemoglobin PF (HPFH) is a benign condition characterized by the persistence of fetal hemoglobin (HbF) in adult red blood cells, typically without clinical symptoms but potentially protective against beta-thalassemia and sickle cell disease complications 1.Diagnosis
Identification of elevated HbF levels above 20% in peripheral blood 1.
Molecular genetic testing to confirm deletion or mutation in the beta-globin gene cluster 1.
Differentiation from other conditions causing elevated HbF through comprehensive hematological evaluation 1.Management
No specific treatment required as HPFH is generally asymptomatic 1.
Monitoring for potential complications in patients with coexisting hemoglobinopathies 1.
Genetic counseling recommended for family members due to hereditary nature 1.Special Populations
Pregnancy: No specific management changes; routine prenatal care advised 1.
Pediatrics: Usually asymptomatic; regular hematological monitoring suggested 1.
Elderly: No unique management strategies beyond general hematological surveillance 1.
Comorbidities: In patients with beta-thalassemia or sickle cell disease, HPFH may confer a protective effect; tailored management based on primary condition 1.Key Recommendations
Confirm diagnosis through molecular genetic testing of the beta-globin gene cluster deletion 1 (Evidence: Strong).
Routine hematological monitoring is advised in pediatric and elderly populations to detect any unforeseen complications 1 (Evidence: Moderate).
Offer genetic counseling to affected individuals and their families due to the hereditary nature of HPFH 1 (Evidence: Expert opinion).References
1 Wang ZF, Sirotkin AM, Buchold GM, Skoultchi AI, Marzluff WF. The mouse histone H1 genes: gene organization and differential regulation. Journal of molecular biology 1997. link